Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-11-14 4:09 pm Purchase | 2025-09-30 | 13G | BRIDGEBIO ONCOLOGY THERAPEUTIC BBOT | Citadel Advisors LLC | 2,538,142 3.200% | 1,215,987 (+91.97%) | Filing History |
| 2025-11-13 09:02 am Purchase | 2025-09-30 | 13G | BRIDGEBIO ONCOLOGY THERAPEUTIC BBOT | Adage Capital Management, L.P. | 1,487,621 1.880% | 1,487,621 (New Position) | Filing History |
| 2025-09-03 3:05 pm Purchase | 2025-09-04 | 13G | BRIDGEBIO ONCOLOGY THERAPEUTIC BBOT | BC Global Opportunities IX LP | 4,365,747 5.500% | 4,365,747 (New Position) | Filing History |
| 2025-08-18 5:59 pm Purchase | 2025-08-11 | 13G | BRIDGEBIO ONCOLOGY THERAPEUTIC BBOT | James E. Flynn | 4,885,446 6.170% | 4,885,446 (New Position) | Filing History |
| 2025-08-18 5:41 pm Purchase | 2025-08-11 | 13D | BRIDGEBIO ONCOLOGY THERAPEUTIC BBOT | BridgeBio Pharma LLC | 13,878,554 17.500% | 13,878,554 (New Position) | Filing History |
| 2025-08-13 08:29 am Purchase | 2025-08-11 | 13D | BRIDGEBIO ONCOLOGY THERAPEUTIC BBOT | Helix Holdings II LLC | 17,878,594 22.600% | 10,489,594 (+141.96%) | Filing History |
| 2025-07-30 4:15 pm Sale | 2025-06-30 | 13G | HELIX ACQUISITION CORP II HLXB | Integrated Core Strategies (US) LLC | 897,251 4.700% | -202,749 (-18.43%) | Filing History |
| 2025-07-24 9:05 pm Purchase | 2025-07-17 | 13G | HELIX ACQUISITION CORP II HLXB | Sculptor Capital LP | 967,460 5.120% | 967,460 (New Position) | Filing History |
| 2025-04-22 11:06 am Sale | 2025-03-31 | 13G | BRIDGEBIO ONCOLOGY THERAPEUTIC BBOT | BlackRock Inc. BLK | 0 0.000% | -1,500,000 (Position Closed) | Filing History |
| 2025-04-15 5:04 pm Purchase | 2025-03-31 | 13G | BRIDGEBIO ONCOLOGY THERAPEUTIC BBOT | BlackRock Portfolio Management LLC | 1,498,865 7.900% | 1,498,865 (New Position) | Filing History |
| 2025-03-04 6:43 pm Sale | 2025-02-28 | 13D | HELIX ACQUISITION CORP II HLXB | Helix Holdings II LLC | 7,389,000 31.590% | -30,000 (-0.40%) | Filing History |
| 2024-11-14 1:22 pm Purchase | 2024-09-30 | 13G | HELIX ACQUISITION CORP II HLXB | PRICE T ROWE ASSOCIATES INC | 1,127,598 6.000% | 1,127,598 (New Position) | Filing History |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | BRIDGEBIO ONCOLOGY THERAPEUTIC BBOT | BlackRock Inc. BLK | 1,500,000 7.900% | 0 (Unchanged) | Filing |
| 2024-10-22 3:24 pm Purchase | 2024-09-30 | 13G | BRIDGEBIO ONCOLOGY THERAPEUTIC BBOT | BlackRock Inc. BLK | 1,500,000 7.900% | 1,500,000 (New Position) | Filing |
| 2024-02-23 4:30 pm Purchase | 2024-02-13 | 13G | HELIX ACQUISITION CORP II HLXB | ADAGE CAPITAL PARTNERS GP L.L.C. | 1,400,000 7.400% | 1,400,000 (New Position) | Filing History |
| 2024-02-23 4:01 pm Purchase | 2024-02-13 | 13G | HELIX ACQUISITION CORP II HLXB | Citadel Advisors LLC | 1,322,155 7.000% | 1,322,155 (New Position) | Filing History |
| 2024-02-20 7:48 pm Purchase | 2024-02-13 | 13D | HELIX ACQUISITION CORP II HLXB | Helix Holdings II LLC | 7,419,000 31.700% | 7,419,000 (New Position) | Filing History |
| 2024-02-15 4:17 pm Purchase | 2024-02-09 | 13G | HELIX ACQUISITION CORP II HLXB | Integrated Core Strategies (US) LLC | 1,100,000 5.800% | 1,100,000 (New Position) | Filing History |